The stock of BroadVision, Inc. (NASDAQ:BVSN) reached all time low today, Apr, 10 and still has $4.05 target or 7.00% below today’s $4.35 share price. This indicates more downside for the $21.57 million company. This technical setup was reported by Barchart.com. If the $4.05 PT is reached, the company will be worth $1.51M less. About 12,124 shares traded or 71.32% up from the average. BroadVision, Inc. (NASDAQ:BVSN) has declined 21.77% since September 1, 2016 and is downtrending. It has underperformed by 30.28% the S&P500.
Intra Cellular Therapies Incorporated (NASDAQ:ITCI) had a decrease of 0.95% in short interest. ITCI’s SI was 5.12M shares in April as released by FINRA. Its down 0.95% from 5.17 million shares previously. With 731,800 avg volume, 7 days are for Intra Cellular Therapies Incorporated (NASDAQ:ITCI)’s short sellers to cover ITCI’s short positions. The SI to Intra Cellular Therapies Incorporated’s float is 14.88%. About 420,578 shares traded. Intra-Cellular Therapies Inc (NASDAQ:ITCI) has declined 65.22% since September 1, 2016 and is downtrending. It has underperformed by 73.73% the S&P500.
Intra-Cellular Therapies, Inc. is a biopharmaceutical company. The company has market cap of $605.03 million. The Firm is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). It currently has negative earnings. The Firm is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
Investors sentiment increased to 1.46 in Q4 2016. Its up 0.52, from 0.94 in 2016Q3. It improved, as 25 investors sold Intra-Cellular Therapies Inc shares while 23 reduced holdings. 27 funds opened positions while 43 raised stakes. 29.52 million shares or 8.32% more from 27.25 million shares in 2016Q3 were reported. Us Comml Bank De stated it has 65 shares or 0% of all its holdings. California State Teachers Retirement Systems holds 70,765 shares. Bancorporation Of America Corporation De holds 6,297 shares. State Street Corp accumulated 972,868 shares. Weiss Multi invested 0.13% in Intra-Cellular Therapies Inc (NASDAQ:ITCI). Tocqueville Asset L P owns 15,125 shares or 0% of their US portfolio. Geode Capital Mngmt Ltd Llc accumulated 262,759 shares or 0% of the stock. Blackrock reported 0% of its portfolio in Intra-Cellular Therapies Inc (NASDAQ:ITCI). Timessquare Capital Lc invested 0.16% in Intra-Cellular Therapies Inc (NASDAQ:ITCI). D E Shaw And Com Incorporated holds 0% in Intra-Cellular Therapies Inc (NASDAQ:ITCI) or 118,390 shares. Amer Group Incorporated holds 19,734 shares. Clough Capital Partners Limited Partnership stated it has 0.35% in Intra-Cellular Therapies Inc (NASDAQ:ITCI). Sei Invests holds 0.01% in Intra-Cellular Therapies Inc (NASDAQ:ITCI) or 112,000 shares. Columbus Circle invested in 0.1% or 519,108 shares. Alliancebernstein L P owns 55,410 shares.
Among 9 analysts covering Intra-Cellular Therapies (NASDAQ:ITCI), 7 have Buy rating, 0 Sell and 2 Hold. Therefore 78% are positive. Intra-Cellular Therapies had 16 analyst reports since August 6, 2015 according to SRatingsIntel. Piper Jaffray initiated the shares of ITCI in report on Thursday, June 2 with “Overweight” rating. As per Thursday, September 29, the company rating was downgraded by SunTrust. The firm earned “Market Outperform” rating on Wednesday, March 9 by JMP Securities. JMP Securities downgraded Intra-Cellular Therapies Inc (NASDAQ:ITCI) on Thursday, September 29 to “Market Perform” rating. The firm earned “Outperform” rating on Friday, November 6 by RBC Capital Markets. The stock of Intra-Cellular Therapies Inc (NASDAQ:ITCI) has “Sell” rating given on Friday, August 7 by Zacks. The stock has “Buy” rating by Guggenheim on Thursday, September 17.
Since November 14, 2016, it had 6 buys, and 5 insider sales for $4.37 million activity. 1,918 shares were sold by Hineline Lawrence J., worth $31,800 on Thursday, January 5. Alafi Christopher D also bought $1.06M worth of Intra-Cellular Therapies Inc (NASDAQ:ITCI) shares. ALAFI MOSHE had bought 65,000 shares worth $1.06M. Shares for $142,773 were sold by Vanover Kimberly E.. 65,000 shares valued at $1.06 million were bought by ALAFI CAPITAL CO LLC on Tuesday, December 6. $26,497 worth of Intra-Cellular Therapies Inc (NASDAQ:ITCI) shares were sold by Halstead Michael. Another trade for 4,081 shares valued at $67,541 was made by Mates Sharon on Thursday, January 5.
BroadVision, Inc. is a provider of e-business solutions. The company has market cap of $21.57 million. The Firm develops, markets and supports enterprise portal applications that allow companies to unify their e-business infrastructure and conduct both interactions and transactions with employees, partners and clients through a self-service model. It currently has negative earnings. It operates through electronic commerce business solutions segment.
